Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

This Analyst Is Bullish On Biohaven’s Approach in Neuro-Psych Space

By Vandana Singh
February 16, 2:58 PM
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset Kv7-7000's Phase 3 trial this year, reducing late-stage risks.

BHVN

Read More
4 minute read

Xenon Pharmaceuticals Outlines Key Milestone Opportunities For 2024; Completion Of Patient Enrollment In XEN1101 Phase 3 X-TOLE2 Clinical Trial In Focal Onset Seizures Anticipated In Second Half Of 2024

By Benzinga Newsdesk
January 8, 9:15 AM
Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half of 2024 XEN1101 Phase 3 Program in Major Depressive Disorder Planned for Initiation in

XENE

Read More
1 minute read

Xenon Pharma’s Depression Candidate Shows Positive Signals Of Efficacy, Despite Primary Endpoint Miss: Analyst

By Vandana Singh
November 27, 3:10 PM
Monday, Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe 

XENE